CAR-T cell therapy for Multiple Myeloma in Israel

Hadassah Hospital has teamed up with NexImmune, an American biotechnology company that specializes in immune-oncology therapies, to create its own patented CAR-T treatment called NXC-201. NXC-201 CAR-T therapy yielded a 90% overall response rate (ORR) in participants with relapsed/refractory multiple myeloma.
https://israelihospitals.org.il/car-t-multiple-myeloma-hadassah-hospital-israel.html

Видео CAR-T cell therapy for Multiple Myeloma in Israel канала Israeli Hospitals Ltd.